Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Chang PY, Huang CC, Hung CH, et al. Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment. Liver Cancer. 2018;7(4):312–322. doi:10.1159/000487608
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109–1113. doi:10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer. 2015;4(3):165–175. doi:10.1159/000367739
   PubMed Web of Science ®Google Scholar
• Woo HY, Jang JW, Choi JY, et al. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2010;45(3):332–339. doi:10.3109/00365520903456573
   PubMed Web of Science ®Google Scholar
• Terzi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57(6):1258–1267. doi:10.1016/j.jhep.2012.07.025
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(1):22–31. doi:10.1159/000368142
   PubMedGoogle Scholar
• Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461–469. doi:10.1053/j.gastro.2006.05.021
   PubMed Web of Science ®Google Scholar
• Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. Front Immunol. 2017;8:1178. doi:10.3389/fimmu.2017.01178
   PubMedGoogle Scholar
• Santodomingo-Garzon T, Swain MG. Role of NKT cells in autoimmune liver disease. Autoimmun Rev. 2011;10(12):793–800. doi:10.1016/j.autrev.2011.06.003
   PubMed Web of Science ®Google Scholar
• Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3(4):e113. doi:10.1371/journal.pbio.0030113
   PubMed Web of Science ®Google Scholar
• Jekarl DW, Lee S, Kwon JH, et al. Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. PLoS One. 2019;14(11):e0224318. doi:10.1371/journal.pone.0224318
   PubMed Web of Science ®Google Scholar
• Fujii SI, Shimizu K. Immune networks and therapeutic targeting of iNKT cells in cancer. Trends Immunol. 2019;40(11):984–997. doi:10.1016/j.it.2019.09.008
   PubMed Web of Science ®Google Scholar
• Gu X, Chu Q, Ma X, et al. New insights into iNKT cells and their roles in liver diseases. Front Immunol. 2022;13:1035950. doi:10.3389/fimmu.2022.1035950
   PubMedGoogle Scholar
• Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol. 2009;182(4):1818–1828. doi:10.4049/jimmunol.0802430
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003;197(12):1667–1676. doi:10.1084/jem.20021650
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol. 2003;122(4):617–622. doi:10.1046/j.1365-2141.2003.04465.x
   PubMed Web of Science ®Google Scholar
• Metelitsa LS, Wu HW, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199(9):1213–1221. doi:10.1084/jem.20031462
   PubMed Web of Science ®Google Scholar
• Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol. 2011;140(2):167–176. doi:10.1016/j.clim.2011.01.009
   PubMed Web of Science ®Google Scholar
• Schneiders FL, de Bruin RC, van den Eertwegh AJ, et al. Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. J Clin Oncol. 2012;30(5):567–570. doi:10.1200/JCO.2011.38.8819
   PubMed Web of Science ®Google Scholar
• Tachibana T, Onodera H, Tsuruyama T, et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005;11(20):7322–7327. doi:10.1158/1078-0432.CCR-05-0877
   PubMed Web of Science ®Google Scholar
• Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001;167(7):4046–4050. doi:10.4049/jimmunol.167.7.4046
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo J, Bao X, et al. Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Oncologist. 2021;26(11):e1919–e1930. doi:10.1002/onco.13899
   PubMed Web of Science ®Google Scholar
• Lu W, Li YH, He XF, Chen Y, Zeng QL, Qiu YR. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma. Di Yi Jun Yi Da Xue Xue Bao. 2002;22(6):524–526.
   PubMedGoogle Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• The European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 Scoring Manual. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf. Accessed January 15, 2018.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44(1):229–241. doi:10.2307/2531910
   PubMed Web of Science ®Google Scholar
• Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002;21(14):1969–1989. doi:10.1002/sim.1193
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Multiple endpoints in clinical trials guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry. Accessed January 15, 2018.
   Google Scholar
• Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol. 2015;62(1 Suppl):S144–56. doi:10.1016/j.jhep.2015.02.007
   PubMedGoogle Scholar
• Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54. doi:10.1148/radiol.2241011262
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4(1):39–50. doi:10.1159/000367727
   PubMed Web of Science ®Google Scholar
• Kudo M. Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. Liver Cancer. 2015;4(2):85–95. doi:10.1159/000367730
   PubMed Web of Science ®Google Scholar
• Kudo M. Locoregional therapy for hepatocellular carcinoma. Liver Cancer. 2015;4(3):163–164. doi:10.1159/000367741
   PubMed Web of Science ®Google Scholar
• Byun J, Kim SY, Kim JH, et al. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging. Acta Radiol. 2021;62(12):1548–1558. doi:10.1177/0284185120971844
   PubMed Web of Science ®Google Scholar
• Hu K, Lu S, Li M, et al. A novel pre-treatment model predicting risk of developing refractoriness to transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer. 2020;11(15):4589–4596. doi:10.7150/jca.44847
   PubMed Web of Science ®Google Scholar
• Feng H, Nakajima N, Wu L, et al. A glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbiol. 2019;10:2157. doi:10.3389/fmicb.2019.02157
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625–636. doi:10.1084/jem.20011786
   PubMed Web of Science ®Google Scholar
• Halder RC, Seki S, Weerasinghe A, Kawamura T, Watanabe H, Abo T. Characterization of NK cells and extrathymic T cells generated in the liver of irradiated mice with a liver shield. Clin Exp Immunol. 1998;114(3):434–447. doi:10.1046/j.1365-2249.1998.00726.x
   PubMed Web of Science ®Google Scholar
• Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol. 2003;3(1):51–62. doi:10.1038/nri981
   PubMed Web of Science ®Google Scholar
• Lei Z, Tang R, Qi Q, et al. Hepatocyte CD1d protects against liver immunopathology in mice with schistosomiasis japonica. Immunology. 2021;162(3):328–338. doi:10.1111/imm.13288
   PubMed Web of Science ®Google Scholar
• Moody DB, Cotton RN. Four pathways of CD1 antigen presentation to T cells. Curr Opin Immunol. 2017;46:127–133. doi:10.1016/j.coi.2017.07.013
   PubMed Web of Science ®Google Scholar
• Lynch L. Adipose invariant natural killer T cells. Immunology. 2014;142(3):337–346. doi:10.1111/imm.12269
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101–117. doi:10.1038/nri3369
   PubMed Web of Science ®Google Scholar
• Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203(12):2639–2648. doi:10.1084/jem.20061097
   PubMed Web of Science ®Google Scholar
• Muzellec L, Bourien H, Edeline J. Patients’ experience of systemic treatment of hepatocellular carcinoma: a review of the impact on quality of life. Cancers. 2021;14(1):179. doi:10.3390/cancers14010179
   PubMed Web of Science ®Google Scholar
• Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30(6):571–579. doi:10.21147/j.issn.1000-9604.2018.06.01
   PubMed Web of Science ®Google Scholar